Biogen
-$1.60 (-0.59%) Today
+$0.37 (+0.14%) As of 12:00 AM UTC after-hours
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.
About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
CEO
Michel Vounatsos
Employees
9,100
Headquarters
Cambridge, Massachusetts
Founded
1978
BIIB Key Statistics
Market Cap
39.96B
Price-Earnings Ratio
21.63
Dividend Yield
—
Average Volume
958.62K
High Today
$271.66
Low Today
$266.30
Open Price
$270.00
Volume
1.80M
52 Week High
$468.55
52 Week Low
$223.25
BIIB News
Reuters11h
Biogen sales face pressure from slow uptake of Alzhiemer's drug
Aduhelm, Biogen's controversial recently approved drug for early Alzheimer's disease, is seen at Butler Hospital, one of the clinical research sites in Providen
Analyst Ratings
52%
of 31 ratings
Buy
51.6%
Hold
48.4%
Sell
0%
BIIB Earnings
$0.00
$3.42
$6.84
$10.26
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
$4.14 per share
Actual
Available Oct 20, Pre-Market
More BIIB News
Barron'sOct 18
Biogen Stock Drops as ALS Trial Fails. Ionis Is Getting Hit Even Harder.
MarketWatch
Shares of Biogen were down 0.6% in premarket trading on Monday, the day after the company said an experimental amyotrophic lateral sclerosis (ALS)
MarketWatchOct 18
Ionis Pharma Shares Drop 12% After Tofersen Study Misses Primary Endpoint
By Chris Wack
Ionis Pharmaceuticals Inc. shares fell 12% to $30.90 after the company said a study for tofersen missed its primary endpoint.
The company said i
MarketWatchOct 18
Biogen says ALS drug did not meet primary endpoint in Phase 3 clinical trial
Shares of Biogen BIIB, -1.43% were down 0.6% in premarket trading on Monday, the day after the company said an experimental amyotrophic lateral sclerosis (ALS)
